Simplex Trading
CYCN icon

Simplex Trading’s Cyclerion Therapeutics CYCN Stock Holding History

Simplex Trading’s Portfolio CYCN Stock Details CYCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-82
Closed – – 9129
2023
Q1 		$0 Sell
82
-10
-11% -$126 ﹤0.01% 9195
2022
Q4 		$1K Buy
92
+57
+163% +$674 ﹤0.01% 8790
2022
Q3 		$0 Sell
35
-135
-79% -$2.32K ﹤0.01% 10054
2022
Q2 		$1K Buy
+170
New +$2.44K ﹤0.01% 9542
2022
Q1 		– Sell
-327
Closed -$7.88K – 10543
2021
Q4 		$11K Buy
+327
New +$15.4K ﹤0.01% 8925
2021
Q2 		– Sell
-337
Closed -$21.1K – 10130
2021
Q1 		$18K Buy
337
+296
+722% +$22.2K ﹤0.01% 7529
2020
Q4 		$2K Buy
41
+35
+583% +$2.39K ﹤0.01% 7960
2020
Q3 		$0 Sell
6
-4
-40% -$457 ﹤0.01% 7889
2020
Q2 		$1K Buy
10
+2
+25% +$167 ﹤0.01% 7350
2020
Q1 		$0 Buy
+8
New +$571 ﹤0.01% 7698

Other funds holding CYCN

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
MP
MFN Partners Boston, Massachusetts $4.77B AUM 72.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Simplex Trading's CYCN Position: Q2 2023 in Review

Simplex Trading sold out of Cyclerion Therapeutics (CYCN) in Q2 2023, closing a stake of 82 shares.

Simplex Trading first reported a position in CYCN in Q1 2020 and held it in 10 quarters. The position peaked at $18K in Q1 2021. 18 funds tracked by Wall St. Rank hold CYCN as of Q2 2023.

  • Simplex Trading reported no remaining Cyclerion Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Simplex Trading sold 82 Cyclerion Therapeutics shares in Q2 2023.
  • Simplex Trading first reported a position in Cyclerion Therapeutics in Q1 2020 and held it in 10 quarters.
  • Simplex Trading's Cyclerion Therapeutics position peaked at $18K in Q1 2021.
  • 18 funds tracked by Wall St. Rank held Cyclerion Therapeutics as of Q2 2023.

Based on Simplex Trading's 13F filing for Q2 2023, filed 4 Aug 2023.